Comparative effects of teriparatide and ibandronate on spine bone mineral density (BMD) and microarchitecture (TBS) in postmenopausal women with osteoporosis: a 2-year open-label study
Summary Treatment effects over 2 years of teriparatide vs. ibandronate in postmenopausal women with osteoporosis were compared using lumbar spine bone mineral density (BMD) and trabecular bone score (TBS). Teriparatide induced larger increases in BMD and TBS compared to ibandronate, suggesting a mor...
Gespeichert in:
| Veröffentlicht in: | Osteoporosis international 2014-07, Vol.25 (7), p.1945-1951 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1951 |
|---|---|
| container_issue | 7 |
| container_start_page | 1945 |
| container_title | Osteoporosis international |
| container_volume | 25 |
| creator | Senn, C. Günther, B. Popp, A. W. Perrelet, R. Hans, D. Lippuner, K. |
| description | Summary
Treatment effects over 2 years of teriparatide vs. ibandronate in postmenopausal women with osteoporosis were compared using lumbar spine bone mineral density (BMD) and trabecular bone score (TBS). Teriparatide induced larger increases in BMD and TBS compared to ibandronate, suggesting a more pronounced effect on bone microarchitecture of the bone anabolic drug.
Introduction
The trabecular bone score (TBS) is an index of bone microarchitecture, independent of bone mineral density (BMD), calculated from anteroposterior spine dual X-ray absorptiometry (DXA) scans. The potential role of TBS for monitoring treatment response with bone-active substances is not established. The aim of this study was to compare the effects of recombinant human 1–34 parathyroid hormone (teriparatide) and the bisphosphonate ibandronate (IBN), on lumbar spine (LS) BMD and TBS in postmenopausal women with osteoporosis.
Methods
Two patient groups with matched age, body mass index (BMI), and baseline LS BMD, treated with either daily subcutaneous teriparatide (
N
= 65) or quarterly intravenous IBN (
N
= 122) during 2 years and with available LS BMD measurements at baseline and 2 years after treatment initiation were compared.
Results
Baseline characteristics (overall mean ± SD) were similar between groups in terms of age 67.9 ± 7.4 years, body mass index 23.8 ± 3.8 kg/m
2
, BMD L1–L4 0.741 ± 0.100 g/cm
2
, and TBS 1.208 ± 0.100. Over 24 months, teriparatide induced a significantly larger increase in LS BMD and TBS than IBN (+7.6 % ± 6.3 vs. +2.9 % ± 3.3 and +4.3 % ± 6.6 vs. +0.3 % ± 4.1, respectively;
P
|
| doi_str_mv | 10.1007/s00198-014-2703-8 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1540232864</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>3327237331</sourcerecordid><originalsourceid>FETCH-LOGICAL-c448t-78135d6521174e33b6050b1f768ace7091a0de8855279b3b44ac029f367c00533</originalsourceid><addsrcrecordid>eNp1kc1u1TAQhS0EoreFB2CDLLG5XRjGP4ljdvRSfqQiFhSJXeQkE-oqsYPtUN034_FwuQUhJDZjj-c7x5YPIU84POcA-kUC4KZhwBUTGiRr7pENV1IyYerqPtmAkZoZxb8ckeOUrqFojNEPyZFQugah1Ib82IV5sdFm9x0pjiP2OdEw0ozRHc4HpNYP1HWlxuBtRho8TYvzSLtQylx20U50QJ9c3tPt2YfXp780s-tjsLG_crn4rhHp9vLs0yl1ni4h5Rl9WOyaivYmlIbeuHxFywDDEmJILr2klgq2RxtpWNCzyXY40ZTXYf-IPBjtlPDx3XpCPr85v9y9Yxcf377fvbpgvVJNZrrhshrqSnCuFUrZ1VBBx0ddN7ZHDYZbGLBpqkpo08lOKduDMKOsdQ9QSXlCtgffJYZvK6bczi71OE3WY1hTyysFQoqmVgV99g96Hdboy-sKJWUNvKpNofiBKn-TUsSxXaKbbdy3HNrbWNtDrG2Jtb2NtW2K5umd89rNOPxR_M6xAOIApDLyXzH-dfV_XX8CaGmueg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1533601569</pqid></control><display><type>article</type><title>Comparative effects of teriparatide and ibandronate on spine bone mineral density (BMD) and microarchitecture (TBS) in postmenopausal women with osteoporosis: a 2-year open-label study</title><source>MEDLINE</source><source>Springer Nature - Complete Springer Journals</source><creator>Senn, C. ; Günther, B. ; Popp, A. W. ; Perrelet, R. ; Hans, D. ; Lippuner, K.</creator><creatorcontrib>Senn, C. ; Günther, B. ; Popp, A. W. ; Perrelet, R. ; Hans, D. ; Lippuner, K.</creatorcontrib><description>Summary
Treatment effects over 2 years of teriparatide vs. ibandronate in postmenopausal women with osteoporosis were compared using lumbar spine bone mineral density (BMD) and trabecular bone score (TBS). Teriparatide induced larger increases in BMD and TBS compared to ibandronate, suggesting a more pronounced effect on bone microarchitecture of the bone anabolic drug.
Introduction
The trabecular bone score (TBS) is an index of bone microarchitecture, independent of bone mineral density (BMD), calculated from anteroposterior spine dual X-ray absorptiometry (DXA) scans. The potential role of TBS for monitoring treatment response with bone-active substances is not established. The aim of this study was to compare the effects of recombinant human 1–34 parathyroid hormone (teriparatide) and the bisphosphonate ibandronate (IBN), on lumbar spine (LS) BMD and TBS in postmenopausal women with osteoporosis.
Methods
Two patient groups with matched age, body mass index (BMI), and baseline LS BMD, treated with either daily subcutaneous teriparatide (
N
= 65) or quarterly intravenous IBN (
N
= 122) during 2 years and with available LS BMD measurements at baseline and 2 years after treatment initiation were compared.
Results
Baseline characteristics (overall mean ± SD) were similar between groups in terms of age 67.9 ± 7.4 years, body mass index 23.8 ± 3.8 kg/m
2
, BMD L1–L4 0.741 ± 0.100 g/cm
2
, and TBS 1.208 ± 0.100. Over 24 months, teriparatide induced a significantly larger increase in LS BMD and TBS than IBN (+7.6 % ± 6.3 vs. +2.9 % ± 3.3 and +4.3 % ± 6.6 vs. +0.3 % ± 4.1, respectively;
P
< 0.0001 for both). LS BMD and TBS were only weakly correlated at baseline (
r
2
= 0.04) with no correlation between the changes in BMD and TBS over 24 months.
Conclusions
In postmenopausal women with osteoporosis, a 2-year treatment with teriparatide led to a significantly larger increase in LS BMD and TBS than IBN, suggesting that teriparatide had more pronounced effects on bone microarchitecture than IBN.</description><identifier>ISSN: 0937-941X</identifier><identifier>EISSN: 1433-2965</identifier><identifier>DOI: 10.1007/s00198-014-2703-8</identifier><identifier>PMID: 24760244</identifier><language>eng</language><publisher>London: Springer London</publisher><subject>Absorptiometry, Photon - methods ; Aged ; Bone density ; Bone Density - drug effects ; Bone Density Conservation Agents - pharmacology ; Bone Density Conservation Agents - therapeutic use ; Comparative studies ; Diphosphonates - pharmacology ; Diphosphonates - therapeutic use ; Drug Evaluation - methods ; Drug therapy ; Endocrine therapy ; Endocrinology ; Female ; Humans ; Injections, Intravenous ; Injections, Subcutaneous ; Lumbar Vertebrae - physiopathology ; Medicine ; Medicine & Public Health ; Menopause ; Middle Aged ; Original Article ; Orthopedics ; Osteoporosis ; Osteoporosis, Postmenopausal - drug therapy ; Osteoporosis, Postmenopausal - physiopathology ; Retrospective Studies ; Rheumatology ; Teriparatide - pharmacology ; Teriparatide - therapeutic use ; Treatment Outcome</subject><ispartof>Osteoporosis international, 2014-07, Vol.25 (7), p.1945-1951</ispartof><rights>International Osteoporosis Foundation and National Osteoporosis Foundation 2014</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c448t-78135d6521174e33b6050b1f768ace7091a0de8855279b3b44ac029f367c00533</citedby><cites>FETCH-LOGICAL-c448t-78135d6521174e33b6050b1f768ace7091a0de8855279b3b44ac029f367c00533</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s00198-014-2703-8$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s00198-014-2703-8$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,777,781,27905,27906,41469,42538,51300</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/24760244$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Senn, C.</creatorcontrib><creatorcontrib>Günther, B.</creatorcontrib><creatorcontrib>Popp, A. W.</creatorcontrib><creatorcontrib>Perrelet, R.</creatorcontrib><creatorcontrib>Hans, D.</creatorcontrib><creatorcontrib>Lippuner, K.</creatorcontrib><title>Comparative effects of teriparatide and ibandronate on spine bone mineral density (BMD) and microarchitecture (TBS) in postmenopausal women with osteoporosis: a 2-year open-label study</title><title>Osteoporosis international</title><addtitle>Osteoporos Int</addtitle><addtitle>Osteoporos Int</addtitle><description>Summary
Treatment effects over 2 years of teriparatide vs. ibandronate in postmenopausal women with osteoporosis were compared using lumbar spine bone mineral density (BMD) and trabecular bone score (TBS). Teriparatide induced larger increases in BMD and TBS compared to ibandronate, suggesting a more pronounced effect on bone microarchitecture of the bone anabolic drug.
Introduction
The trabecular bone score (TBS) is an index of bone microarchitecture, independent of bone mineral density (BMD), calculated from anteroposterior spine dual X-ray absorptiometry (DXA) scans. The potential role of TBS for monitoring treatment response with bone-active substances is not established. The aim of this study was to compare the effects of recombinant human 1–34 parathyroid hormone (teriparatide) and the bisphosphonate ibandronate (IBN), on lumbar spine (LS) BMD and TBS in postmenopausal women with osteoporosis.
Methods
Two patient groups with matched age, body mass index (BMI), and baseline LS BMD, treated with either daily subcutaneous teriparatide (
N
= 65) or quarterly intravenous IBN (
N
= 122) during 2 years and with available LS BMD measurements at baseline and 2 years after treatment initiation were compared.
Results
Baseline characteristics (overall mean ± SD) were similar between groups in terms of age 67.9 ± 7.4 years, body mass index 23.8 ± 3.8 kg/m
2
, BMD L1–L4 0.741 ± 0.100 g/cm
2
, and TBS 1.208 ± 0.100. Over 24 months, teriparatide induced a significantly larger increase in LS BMD and TBS than IBN (+7.6 % ± 6.3 vs. +2.9 % ± 3.3 and +4.3 % ± 6.6 vs. +0.3 % ± 4.1, respectively;
P
< 0.0001 for both). LS BMD and TBS were only weakly correlated at baseline (
r
2
= 0.04) with no correlation between the changes in BMD and TBS over 24 months.
Conclusions
In postmenopausal women with osteoporosis, a 2-year treatment with teriparatide led to a significantly larger increase in LS BMD and TBS than IBN, suggesting that teriparatide had more pronounced effects on bone microarchitecture than IBN.</description><subject>Absorptiometry, Photon - methods</subject><subject>Aged</subject><subject>Bone density</subject><subject>Bone Density - drug effects</subject><subject>Bone Density Conservation Agents - pharmacology</subject><subject>Bone Density Conservation Agents - therapeutic use</subject><subject>Comparative studies</subject><subject>Diphosphonates - pharmacology</subject><subject>Diphosphonates - therapeutic use</subject><subject>Drug Evaluation - methods</subject><subject>Drug therapy</subject><subject>Endocrine therapy</subject><subject>Endocrinology</subject><subject>Female</subject><subject>Humans</subject><subject>Injections, Intravenous</subject><subject>Injections, Subcutaneous</subject><subject>Lumbar Vertebrae - physiopathology</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Menopause</subject><subject>Middle Aged</subject><subject>Original Article</subject><subject>Orthopedics</subject><subject>Osteoporosis</subject><subject>Osteoporosis, Postmenopausal - drug therapy</subject><subject>Osteoporosis, Postmenopausal - physiopathology</subject><subject>Retrospective Studies</subject><subject>Rheumatology</subject><subject>Teriparatide - pharmacology</subject><subject>Teriparatide - therapeutic use</subject><subject>Treatment Outcome</subject><issn>0937-941X</issn><issn>1433-2965</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2014</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><recordid>eNp1kc1u1TAQhS0EoreFB2CDLLG5XRjGP4ljdvRSfqQiFhSJXeQkE-oqsYPtUN034_FwuQUhJDZjj-c7x5YPIU84POcA-kUC4KZhwBUTGiRr7pENV1IyYerqPtmAkZoZxb8ckeOUrqFojNEPyZFQugah1Ib82IV5sdFm9x0pjiP2OdEw0ozRHc4HpNYP1HWlxuBtRho8TYvzSLtQylx20U50QJ9c3tPt2YfXp780s-tjsLG_crn4rhHp9vLs0yl1ni4h5Rl9WOyaivYmlIbeuHxFywDDEmJILr2klgq2RxtpWNCzyXY40ZTXYf-IPBjtlPDx3XpCPr85v9y9Yxcf377fvbpgvVJNZrrhshrqSnCuFUrZ1VBBx0ddN7ZHDYZbGLBpqkpo08lOKduDMKOsdQ9QSXlCtgffJYZvK6bczi71OE3WY1hTyysFQoqmVgV99g96Hdboy-sKJWUNvKpNofiBKn-TUsSxXaKbbdy3HNrbWNtDrG2Jtb2NtW2K5umd89rNOPxR_M6xAOIApDLyXzH-dfV_XX8CaGmueg</recordid><startdate>20140701</startdate><enddate>20140701</enddate><creator>Senn, C.</creator><creator>Günther, B.</creator><creator>Popp, A. W.</creator><creator>Perrelet, R.</creator><creator>Hans, D.</creator><creator>Lippuner, K.</creator><general>Springer London</general><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QP</scope><scope>7RV</scope><scope>7TS</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>KB0</scope><scope>M0S</scope><scope>M1P</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope></search><sort><creationdate>20140701</creationdate><title>Comparative effects of teriparatide and ibandronate on spine bone mineral density (BMD) and microarchitecture (TBS) in postmenopausal women with osteoporosis: a 2-year open-label study</title><author>Senn, C. ; Günther, B. ; Popp, A. W. ; Perrelet, R. ; Hans, D. ; Lippuner, K.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c448t-78135d6521174e33b6050b1f768ace7091a0de8855279b3b44ac029f367c00533</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2014</creationdate><topic>Absorptiometry, Photon - methods</topic><topic>Aged</topic><topic>Bone density</topic><topic>Bone Density - drug effects</topic><topic>Bone Density Conservation Agents - pharmacology</topic><topic>Bone Density Conservation Agents - therapeutic use</topic><topic>Comparative studies</topic><topic>Diphosphonates - pharmacology</topic><topic>Diphosphonates - therapeutic use</topic><topic>Drug Evaluation - methods</topic><topic>Drug therapy</topic><topic>Endocrine therapy</topic><topic>Endocrinology</topic><topic>Female</topic><topic>Humans</topic><topic>Injections, Intravenous</topic><topic>Injections, Subcutaneous</topic><topic>Lumbar Vertebrae - physiopathology</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Menopause</topic><topic>Middle Aged</topic><topic>Original Article</topic><topic>Orthopedics</topic><topic>Osteoporosis</topic><topic>Osteoporosis, Postmenopausal - drug therapy</topic><topic>Osteoporosis, Postmenopausal - physiopathology</topic><topic>Retrospective Studies</topic><topic>Rheumatology</topic><topic>Teriparatide - pharmacology</topic><topic>Teriparatide - therapeutic use</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Senn, C.</creatorcontrib><creatorcontrib>Günther, B.</creatorcontrib><creatorcontrib>Popp, A. W.</creatorcontrib><creatorcontrib>Perrelet, R.</creatorcontrib><creatorcontrib>Hans, D.</creatorcontrib><creatorcontrib>Lippuner, K.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Calcium & Calcified Tissue Abstracts</collection><collection>Nursing & Allied Health Database</collection><collection>Physical Education Index</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>ProQuest Public Health Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><jtitle>Osteoporosis international</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Senn, C.</au><au>Günther, B.</au><au>Popp, A. W.</au><au>Perrelet, R.</au><au>Hans, D.</au><au>Lippuner, K.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Comparative effects of teriparatide and ibandronate on spine bone mineral density (BMD) and microarchitecture (TBS) in postmenopausal women with osteoporosis: a 2-year open-label study</atitle><jtitle>Osteoporosis international</jtitle><stitle>Osteoporos Int</stitle><addtitle>Osteoporos Int</addtitle><date>2014-07-01</date><risdate>2014</risdate><volume>25</volume><issue>7</issue><spage>1945</spage><epage>1951</epage><pages>1945-1951</pages><issn>0937-941X</issn><eissn>1433-2965</eissn><abstract>Summary
Treatment effects over 2 years of teriparatide vs. ibandronate in postmenopausal women with osteoporosis were compared using lumbar spine bone mineral density (BMD) and trabecular bone score (TBS). Teriparatide induced larger increases in BMD and TBS compared to ibandronate, suggesting a more pronounced effect on bone microarchitecture of the bone anabolic drug.
Introduction
The trabecular bone score (TBS) is an index of bone microarchitecture, independent of bone mineral density (BMD), calculated from anteroposterior spine dual X-ray absorptiometry (DXA) scans. The potential role of TBS for monitoring treatment response with bone-active substances is not established. The aim of this study was to compare the effects of recombinant human 1–34 parathyroid hormone (teriparatide) and the bisphosphonate ibandronate (IBN), on lumbar spine (LS) BMD and TBS in postmenopausal women with osteoporosis.
Methods
Two patient groups with matched age, body mass index (BMI), and baseline LS BMD, treated with either daily subcutaneous teriparatide (
N
= 65) or quarterly intravenous IBN (
N
= 122) during 2 years and with available LS BMD measurements at baseline and 2 years after treatment initiation were compared.
Results
Baseline characteristics (overall mean ± SD) were similar between groups in terms of age 67.9 ± 7.4 years, body mass index 23.8 ± 3.8 kg/m
2
, BMD L1–L4 0.741 ± 0.100 g/cm
2
, and TBS 1.208 ± 0.100. Over 24 months, teriparatide induced a significantly larger increase in LS BMD and TBS than IBN (+7.6 % ± 6.3 vs. +2.9 % ± 3.3 and +4.3 % ± 6.6 vs. +0.3 % ± 4.1, respectively;
P
< 0.0001 for both). LS BMD and TBS were only weakly correlated at baseline (
r
2
= 0.04) with no correlation between the changes in BMD and TBS over 24 months.
Conclusions
In postmenopausal women with osteoporosis, a 2-year treatment with teriparatide led to a significantly larger increase in LS BMD and TBS than IBN, suggesting that teriparatide had more pronounced effects on bone microarchitecture than IBN.</abstract><cop>London</cop><pub>Springer London</pub><pmid>24760244</pmid><doi>10.1007/s00198-014-2703-8</doi><tpages>7</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0937-941X |
| ispartof | Osteoporosis international, 2014-07, Vol.25 (7), p.1945-1951 |
| issn | 0937-941X 1433-2965 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1540232864 |
| source | MEDLINE; Springer Nature - Complete Springer Journals |
| subjects | Absorptiometry, Photon - methods Aged Bone density Bone Density - drug effects Bone Density Conservation Agents - pharmacology Bone Density Conservation Agents - therapeutic use Comparative studies Diphosphonates - pharmacology Diphosphonates - therapeutic use Drug Evaluation - methods Drug therapy Endocrine therapy Endocrinology Female Humans Injections, Intravenous Injections, Subcutaneous Lumbar Vertebrae - physiopathology Medicine Medicine & Public Health Menopause Middle Aged Original Article Orthopedics Osteoporosis Osteoporosis, Postmenopausal - drug therapy Osteoporosis, Postmenopausal - physiopathology Retrospective Studies Rheumatology Teriparatide - pharmacology Teriparatide - therapeutic use Treatment Outcome |
| title | Comparative effects of teriparatide and ibandronate on spine bone mineral density (BMD) and microarchitecture (TBS) in postmenopausal women with osteoporosis: a 2-year open-label study |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-20T14%3A10%3A27IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Comparative%20effects%20of%20teriparatide%20and%20ibandronate%20on%20spine%20bone%20mineral%20density%20(BMD)%20and%20microarchitecture%20(TBS)%20in%20postmenopausal%20women%20with%20osteoporosis:%20a%202-year%20open-label%20study&rft.jtitle=Osteoporosis%20international&rft.au=Senn,%20C.&rft.date=2014-07-01&rft.volume=25&rft.issue=7&rft.spage=1945&rft.epage=1951&rft.pages=1945-1951&rft.issn=0937-941X&rft.eissn=1433-2965&rft_id=info:doi/10.1007/s00198-014-2703-8&rft_dat=%3Cproquest_cross%3E3327237331%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1533601569&rft_id=info:pmid/24760244&rfr_iscdi=true |